Karcinom plu}a je naj~e{}e maligno oboljenje kod mu{kog pola, a u `ena na drugom mestu (nakon

raka dojke). Klini~ka podela na nemikrocelularni (NSCLC) i

mikrocelularni (SCLC) odra`ava razli~ito biolo{ko pona{anje i
sledstveno razlike u terapijskom pristupu. Od velike va`nosti
bi bilo postojanje biomarkera koji bi omogu}ili razlikovanje
ova dva tipa karcinoma plu}a, naro~ito u slu~ajeva kada nije
izvodljiva invazivna dijagnostika kao i u pra}enju efekata terapije i ranom otkrivanju relapsa bolesti.
Rezultati velikih retrospektivnih ili prospektivnih studija ukazuju na izvesnu vrednost specifi~nih
markera ili kombinacija ovih markera za dijagnosti~ke i diferencijalno dijagnosti~ke svrhe. Merenje
~etiri
serum tumor markera, CYFRA 21-1, CEA, NSE i ProGRP ima
opravdanja da bi se identifikovao vode}i marker i na taj na~in
predpostavio verovatni histolo{ki tip tumora. Serijska odre-
|ivanja odgovaraju}eg tumor markera mo`e tako|e biti od
pomo}i da se utvrdi kompletnost uklanjanja tumora i utvrdi
relaps bolesti u okultnom klini~kom stadijumu.
Klju~ne re~i: karcinom plu}a, CEA, hromogranin A, NSE,
gastrin osloba|aju}i peptid, CYFRA 21-1, antigen skvamocelularnog karcinoma (SCCA)
Summary: Lung cancer is the most frequent malignancy
among men, and the second frequent among women (after
breast cancer). Clinical calssification of lung cancer to nonsmall cell lung cancer (NSCLC) and small cell
lung cancer
(SCLC) type reflects their different biological behaviour and
consequently differences in treatment management. Biomarkers that would allow differentiation
between these two tumor
types, especially for diagnosis of the cases not eligible for invasive diagnostic procedures, and in
monitoring the treatment
effect as well as for early detection of disease relapse would be
of enormous importance. Large retrospective and prospective
clinical trials have proved certain usefullness of serum tumor
markers for lung cancer diagnosis and differential diagnosis.
Serum measurement of four tumor markers concentrations,
CYFRA 21-1, CEA, NSE i ProGRP is reasonable in order to
identify the leading marker thus highly suggestive of specific
lung tumor hystology. Serial determinations of the appropriate
tumor marker may help assess the completeness of tumo